Synthetic Genomics, Inc. has entered a research and licensing option agreement with Janssen Vaccines & Prevention B.V., to apply its replicon RNA technology for the design and development of novel RNA-based medicines for infectious diseases. The agreement was facilitated by Johnson & Johnson Innovation.    Synthetic Genomics replicon RNA technology enables a tunable, multigenic approach to elicit desired antigen expression and immune response for a variety of applications. The company ...